Sampath, Deepak

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 3,058

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 541

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 440

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences

Cancer, Hypoxia, and MetabolismPancreatic and Hepatic Oncology Research

Cited by 398

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition

Boudreau, A., Purkey, H. E., Hitz, A., Robarge, K., Peterson, D., Labadie, S., Kwong, M., Hong, R., Gao, M., Del Nagro, C., et al. (2016) · Nature Chemical Biology

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 280

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer

Sampath, D., Zabka, T. S., Misner, D. L., O’Brien, T., & Dragovich, P. S. (2015) · Pharmacology & Therapeutics

Sirtuins and Resveratrol in MedicineBiochemical and Molecular Research

Cited by 258

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer

Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 183

Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade

Kohlhapp, F. J., Haribhai, D., Mathew, R., Duggan, R., Ellis, P. A., Wang, R., Lasater, E. A., Shi, Y., Dave, N., Riehm, J. J., et al. (2021) · Cancer Discovery

Cancer Immunotherapy and BiomarkersCell death mechanisms and regulation

Cited by 126

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)

Dragovich, P. S., Adhikari, P., Blake, R. A., Blaquiere, N., Chen, J., Cheng, Y.-X., den Besten, W., Han, J., Hartman, S. J., He, J., et al. (2020) · Bioorganic & Medicinal Chemistry Letters

Protein Degradation and InhibitorsMonoclonal and Polyclonal Antibodies Research

Cited by 120

Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways

Pham, T. H., Hagenbeek, T. J., Lee, H.-J., Li, J., Rose, C. M., Lin, E., Yu, M., Martin, S. E., Piskol, R., Lacap, J. A., et al. (2021) · Cancer Discovery

Hippo pathway signaling and YAP/TAZCancer-related molecular mechanisms research

Cited by 64